Companion Diagnostics Partnering Terms & Agreements -





 Publication date: April 2014 | Version: 7 | Pages: 378

 

The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors companion diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

 

This report contains over 250 links to online copies of actual companion diagnostics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of companion diagnostics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in companion diagnostics dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

                    

Chapter 3 provides a review of the leading companion diagnostics deals since 2009. Deals are listed by headline value and signed by big pharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies where companion diagnostic deals are available followed by a brief summary as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive and detailed review of companion diagnosticss partnering deals signed and announced since January 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of companion diagnostics partnering deals signed and announced since January 2009. The chapter is organized by companion diagnostics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in companion diagnostics partnering and dealmaking since 2009. The Appendix toward the end includes all the companion diagnostics deals since 2009 by company A-Z, deal type and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of companion diagnostics technologies and products.

 

 Report scope 

 

 Companion Diagnostics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to companion diagnostics trends and structure of deals entered into by leading companies worldwide.

 

 Companion Diagnostics Partnering Terms and Agreements includes:

o Trends in companion diagnostics dealmaking in the biopharma industry since 2009

o Analysis of companion diagnostics deal structure

o Access to headline, upfront, milestone and royalty data

o Case studies of real-life companion diagnostics deals

o Access to companion diagnostics contract documents

o The leading companion diagnostics deals by value since 2009

o Most active companion diagnostics dealmakers since 2009

o The leading companion diagnostics partnering resources

 

In Companion Diagnostics Partnering Terms and Agreements, the available contracts are listed by:

o Company A-Z

o Headline value

o Stage of development at signing

o Deal component type

o Specific therapy target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 250 companion diagnostics deals. Analyzing actual contract agreements allows assessment of the following:

 

o What are the precise companion diagnostics rights granted or optioned?

o What is actually granted by the agreement to the partner company?

o What exclusivity is granted?

o What is the payment structure for the deal?

o How are sales and payments audited?

o What is the deal term?

o How are the key terms of the agreement defined?

o How are IPRs handled and owned?

o Who is responsible for commercialization?

o Who is responsible for development, supply, and manufacture?

o What happens when there is a change of ownership?

o What sublicensing and subcontracting provisions have been agreed?

o Which boilerplate clauses does the company insist upon?

o Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

o Which jurisdiction does the company insist upon for agreement law?

 

Number of pages: The report compises of 378 pages..

 

TABLE OF CONTENTS 

  

Executive Summary 

  

Chapter 1 – Introduction 

  

Chapter 2 – Trends in companion diagnostics dealmaking 

  

2.1. Introduction

2.2. Companion diagnostics partnering over the years

2.3. Big pharma companion diagnostics dealmaking activity

2.4. Most active companion diagnostics dealmakers

2.5. Companion diagnostics partnering by deal type

2.6. Companion diagnostics partnering by disease type

2.7 Average deal terms for companion diagnosticss

2.7.1 Companion diagnostics headline values

2.7.2 Companion diagnostics upfront payments

2.7.3 Companion diagnostics milestone payments

2.7.4 Companion diagnosticss royalty rates

2.8. The anatomy of companion diagnostics partnering

2.8. The anatomy of a companion diagnostics deal

2.8.a. Case study 1: Achaogen, ARK Diagnostics - Aug 2013

2.8.b. Case study 2: Salix Pharmaceuticals, Photcure ASA – Oct 2010

 

Chapter 3 – Leading companion diagnostics deals 

 

3.1. Introduction

3.2. Companion diagnostics deals by value

3.3. Top companion diagnostics deals involving big pharma

 

Chapter 4 – Big pharma companion diagnostics deals 

 

4.1. Introduction

4.2. How to use big pharma companion diagnostics partnering deals

4.3. Big pharma companion diagnostics partnering company profiles

Abbott

Amgen

Astellas

AstraZeneca

Bayer

Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

Eisai

Eli Lilly

GlaxoSmithKline

Johnson & Johnson

Merck & Co

Merck KGaA

Novartis

Pfizer

Roche

Sanofi

Servier

Takeda

UCB

 

Chapter 5 – Companion diagnostics contracts dealmaking directory 

  

5.1. Introduction

5.2. Companion Diagnostics deals by company A-Z with contracts

5.3. Companion Diagnostics deals by stage of development with contracts

Discovery

Preclinical

5.4. Companion Diagnostics deals by deal type with contracts

Co-development

Collaborative R&D

Contract service

Development

Distribution

Licensing

Marketing

Option

Sub-license

5.5. Companion Diagnostics deals by therapy area with contracts

Cardiovascular

Central Nervous System

Infectives

Metabolic

Oncology

Psychiatry

 

Chapter 6 – Companion diagnostics dealmaking by technology type 

 

6.1. Introduction

Companion Diagnostics

 

Chapter 7 – Companion diagnostics partnering resource center 

 

7.1. Online companion diagnosticss partnering

7.2. Companion diagnostics partnering events

7.3. Further reading on companion diagnostics dealmaking

7.4. Deal type definitions

 

Appendices 

Appendix 1 – Companion Diagnostics deals by company A-Z

Appendix 2 – Companion Diagnostics deals by deal type

Appendix 3– Companion Diagnostics deals by therapy type

 

 

About Wildwood Ventures

Current Partnering

Current Agreements

Recent titles from CurrentPartnering

Order Form – Technology Reports

Order Form – Therapy Reports

 

 Table of figures 

 

Figure 1: Companion diagnostics partnering since 2009

Figure 2: Big pharma – top 50 – companion diagnostics deals 2009 to 2014

Figure 3: Big pharma companion diagnostics deal frequency – 2009 to 2014

Figure 4: Active companion diagnosticss dealmaking activity– 2009 to 2014

Figure 5: Companion diagnostics partnering by deal type since 2009

Figure 6: Companion diagnostics partnering by disease type since 2009

Figure 7: Companion diagnostics partnering by oncology target since 2009

Figure 8: Companion diagnostics deals with a headline value

Figure 9: Companion diagnostics deal headline value distribution, US$million -Disovery

Figure 10: Companion diagnostics deal headline value distribution, US$million -Preclinical

Figure 11: Companion diagnostics deal headline value distribution, US$million –Phase 1

Figure 12: Companion diagnostics deal headline value distribution, US$million –Phase II

Figure 13: Companion diagnostics deal headline value distribution, US$million -Marketed

Figure 14: Summary median headline value by stage of development, 2009-2014

Figure 15: Companion diagnostics deals with upfront payment values

Figure 16: Companion diagnostics deal upfront value distribution, US$million – 2009-2014 – Discovery

Figure 17: Companion diagnostics deal upfront value distribution, US$million – 2009-2014 – Preclinical

Figure 18: Companion diagnostics deal upfront value distribution, US$million – 2009-2014 – Phase I

Figure 19: Companion diagnostics deal upfront value distribution, US$million – 2009-2014 – Phase II

Figure 20: Companion diagnostics deal upfront value distribution, US$million – 2009-2014 – Phase III

Figure 21: Companion diagnostics deal upfront value distribution, US$million – 2009-2014 – Regulatory

Figure 22: Companion diagnostics deal upfront value distribution, US$million – 2009-2014 – Marketed

Figure 23: Summary median upfront value by stage of development, 2009-2014

Figure 24: Companion diagnostics deals with milestone payments values

Figure 25: Companion diagnostics deal milestone value distribution, US$million – 2009-2014 – Discovery

Figure 26: Companion diagnostics deal milestone value distribution, US$million – 2009-2014 – Preclinical

Figure 27: Companion diagnostics deal milestone value distribution, US$million – 2009-2014 – Phase I

Figure 28: Companion diagnostics deal milestone value distribution, US$million – 2009-2014 – Phase II

Figure 29: Companion diagnostics deal milestone value distribution, US$million – 2009-2014 – Phase III

Figure 30: Companion diagnostics deal milestone value distribution, US$million – 2009-2014 – Regulatory

Figure 31: Companion diagnostics deal milestone value distribution, US$million – 2009-2014 – Marketed

Figure 32: Companion diagnostics deals with royalty rates values

Figure 33: Companion diagnostics deal royalty rate  value distribution, US$million – 2009-2014 – Discovery

Figure 34: Companion diagnostics deal royalty rate value distribution, US$million – 2009-2014 – Preclinical

Figure 35: Companion diagnostics deal royalty rate value distribution, US$million – 2009-2014 – Phase I

Figure 36: Companion diagnostics deal royalty rates value distribution, US$million – 2009-2013– Phase II

Figure 37: Companion diagnostics deal royalty rate value distribution, US$million – 2009-2014 –  Phase III

Figure 38: Companion diagnostics deal royalty rate value distribution, US$million – 2009-2014 –  Regulatory

Figure 39: Companion diagnostics deal royalty rate value distribution, US$million – 2009-2014 – Marketed

Figure 40: Summary median royalty rate value by stage of development, 2009-2014

Figure 41: Components of the typical companion diagnostics deal structure

Figure 42: Top companion diagnostics deals by value since 2009

Figure 43: Top companion diagnostics deals signed by big pharma value since 2009

Figure 44: Online partnering resources

Figure 45: Forthcoming partnering events